PORTLAND, OR--(Marketwire - May 27, 2008) - MolecularMD Corp., a developer and provider of cancer-based molecular diagnostics, announced today that it has entered into a license agreement with the Oregon Health & Science University to obtain exclusive commercial rights to patented intellectual property (USPTO Patent # 7326534) related to the detection of Gleevec® (imatinib) resistant BCR-ABL mutations.
